Los Angeles, CA — June 20, 2018 — Oncology is both an area of immense clinical need and a primary driver of healthcare spending. As a result, cancer care is a focus of extensive debate around value.

In short, the field of oncology offers a unique opportunity to develop patient-centered, robust, and flexible models for understanding the value of care. New therapies to treat lung cancers give great hope to patients and present questions for many healthcare stakeholders.

That’s why the Innovation and Value Initiative (IVI) is pleased to collaborate with LUNGevity, an organization dedicated to advancing research for lung cancer and advocating for patients, on our next Open-Source Value Project (OSVP) modeling platform, which will focus on non-small cell lung cancer.

This collaboration with LUNGevity ensures that input from the patient community is at the forefront of all model development to assess value in lung cancer therapies.
Specifically, our next OSVP modeling platform will focus on epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC). Approximately 20% of new lung cancer cases are EGFR+ NSCLC, with 45,750 people diagnosed with EGFR+ NSCLC every year. Despite rapid innovation in treatment, the probability of survival at 5 years is only 4.7%.

Our selection of EGFR+ NSCLC was guided by discussions with oncologists, researchers, members of IVI’s Strategic Advisory Panel, and most importantly, numerous members of the patient advocacy and support community.

IVI’s goal is that with a variety of data on lung cancer therapies – including insights from actual patients – our open-source value model will create deeper insights about lung cancer value for patients, payers, employers and health systems.

To kick off the platform development, IVI and LUNGevity will conduct research quantifying the patient experience with this disease. This research will include patient focus groups followed by a quantitative survey examining drivers of value, preferences in treatment, and other key contextual questions. The research will help inform the structure and content of OSVP patient simulations and decision models.

We currently plan to release the first version of the non-small lung cancer platform in November, which will be followed by an open public comment period.

Media Contact
Eric Hoffman
Schmidt Public Affairs
Telephone: (202) 285-0810
E-Mail: ehoffman@schmidtpa.com

Follow IVI on Twitter: @IVI_health
Follow IVI on Facebook: @innovationandvalueinitiative
Follow IVI on LinkedIn: Innovation and Value Initiative

About the Innovation and Value Initiative
The Innovation and Value Initiative (IVI) is a collaboration among thought leaders in academia, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and other organizations. It was created to raise the level of discussion regarding value in health care and find common ground in the approach to measuring and rewarding value. IVI’s Strategic Advisory Panel includes experienced leaders from across the health care industry. Their role is to provide advice and ensure the credibility and rigor in the research and policy products and to ensure all parties have a voice in IVI activities.